Literature DB >> 31175103

Intravenous Iron Use in the Care of Patients with Kidney Disease.

Iain C Macdougall1.   

Abstract

Entities:  

Keywords:  Administration, Intravenous; Anemia; Infusions, Intravenous; Injections, Intravenous; Iron; hemodialysis; intravenous iron; kidney disease; non-dialysis

Mesh：

Substances：

Year:  2019        PMID： 31175103      PMCID： PMC6777593          DOI： 10.2215/CJN.00510119

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  11 in total

1.  Randomized trial of intravenous iron-induced hypophosphatemia.

Authors:  Myles Wolf; Glenn M Chertow; Iain C Macdougall; Robert Kaper; Julie Krop; William Strauss
Journal:  JCI Insight       Date:  2018-12-06

2.  Iron management in chronic kidney disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.

Authors:  Iain C Macdougall; Andreas J Bircher; Kai-Uwe Eckardt; Gregorio T Obrador; Carol A Pollock; Peter Stenvinkel; Dorine W Swinkels; Christoph Wanner; Günter Weiss; Glenn M Chertow
Journal:  Kidney Int       Date:  2016-01       Impact factor: 10.612

Review 3.  Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis.

Authors:  Daniel Shepshelovich; Benaya Rozen-Zvi; Tomer Avni; Uzi Gafter; Anat Gafter-Gvili
Journal:  Am J Kidney Dis       Date:  2016-06-16       Impact factor: 8.860

4.  Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions.

Authors:  Palle Bager; Christian L Hvas; Jens F Dahlerup
Journal:  Br J Clin Pharmacol       Date:  2017-01-18       Impact factor: 4.335

5.  Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004.

Authors:  Steven Fishbane; Simcha Pollack; Harold I Feldman; Marshall M Joffe
Journal:  Clin J Am Soc Nephrol       Date:  2008-11-05       Impact factor: 8.237

6.  Intravenous Iron in Patients Undergoing Maintenance Hemodialysis.

Authors:  Iain C Macdougall; Claire White; Stefan D Anker; Sunil Bhandari; Kenneth Farrington; Philip A Kalra; John J V McMurray; Heather Murray; Charles R V Tomson; David C Wheeler; Christopher G Winearls; Ian Ford
Journal:  N Engl J Med       Date:  2018-10-26       Impact factor: 91.245

7.  A randomized trial of intravenous and oral iron in chronic kidney disease.

Authors:  Rajiv Agarwal; John W Kusek; Maria K Pappas
Journal:  Kidney Int       Date:  2015-06-17       Impact factor: 10.612

Review 8.  Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis.

Authors:  Zoe Tolkien; Lynne Stecher; Adrian P Mander; Dora I A Pereira; Jonathan J Powell
Journal:  PLoS One       Date:  2015-02-20       Impact factor: 3.240

9.  Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017.

Authors:  Birgit Ehlken; Lennart Nathell; Annegret Gohlke; Derya Bocuk; Massoud Toussi; Stefan Wohlfeil
Journal:  Drug Saf       Date:  2019-03       Impact factor: 5.606

10.  FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.

Authors:  Iain C Macdougall; Andreas H Bock; Fernando Carrera; Kai-Uwe Eckardt; Carlo Gaillard; David Van Wyck; Bernard Roubert; Jacqueline G Nolen; Simon D Roger
Journal:  Nephrol Dial Transplant       Date:  2014-06-02       Impact factor: 5.992
View more
  1 in total

1.  The Value of Intravenous Iron: Beyond the Cave of Speculation.

Authors:  Daniel W Coyne; Steven Fishbane
Journal:  J Am Soc Nephrol       Date:  2020-04-06       Impact factor: 10.121
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.